Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia

Ítems similars

• A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(®)) in client‐owned dogs with atopic dermatitis
  per: Cosgrove, Sallie B., et al.
  Publicat: (2013)
• A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs
  per: Little, Peter R, et al.
  Publicat: (2015)
• Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis
  per: Cosgrove, Sallie B, et al.
  Publicat: (2013)
• Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
  per: Gonzales, A J, et al.
  Publicat: (2014)
• An open, self-controlled study on the efficacy of topical indoxacarb for eliminating fleas and clinical signs of flea-allergy dermatitis in client-owned dogs in Queensland, Australia
  per: Fisara, Petr, et al.
  Publicat: (2014)